The recently released first volume of Navigating the Path Forward for Dementia in Canada: The Landmark Study predicts a significant increase in the number of Canadians living with dementia over the next three decades.
Ryaltris was approved for symptomatic treatment of moderate to severe seasonal allergic rhinitis and associated ocular symptoms in people over six years old.